Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Deng L, Li Z, Zhang H, Huang H, Hu J, Liu L, Liu T, Jin J, Zhu Z, Li W, Huang Z, Huang W, Zhou K, Yang H, Zhang M, Ding K, Zhou H, Hu Y, Shuang Y, Cao J, Gao S, Li D, Sun Z, Zhang Q, Yi S, Ji C, Zhang L, Hou C, Du Y, Wang W, Zhao R, Song Y, Zhu J.
Deng L, et al. Among authors: hou c.
Am J Hematol. 2023 Nov;98(11):1742-1750. doi: 10.1002/ajh.27064. Epub 2023 Aug 30.
Am J Hematol. 2023.
PMID: 37647123
Free article.